JP7039579B2 - 抗癌剤としての４－アニリノ－キノリン化合物 - Google Patents

抗癌剤としての４－アニリノ－キノリン化合物 Download PDF

Info

Publication number
JP7039579B2
JP7039579B2 JP2019521185A JP2019521185A JP7039579B2 JP 7039579 B2 JP7039579 B2 JP 7039579B2 JP 2019521185 A JP2019521185 A JP 2019521185A JP 2019521185 A JP2019521185 A JP 2019521185A JP 7039579 B2 JP7039579 B2 JP 7039579B2
Authority
JP
Japan
Prior art keywords
amine
quinoline
methoxyphenyl
compound
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019521185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521193A5 (enExample
JP2019521193A (ja
Inventor
ティエリー・パッスロン
ラシッド・ベンヒーダ
パスカル・ダオ
ジャン・マルコ・デ・ドナティス
アントニー・マルタン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2019521193A publication Critical patent/JP2019521193A/ja
Publication of JP2019521193A5 publication Critical patent/JP2019521193A5/ja
Application granted granted Critical
Publication of JP7039579B2 publication Critical patent/JP7039579B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019521185A 2016-07-08 2017-07-10 抗癌剤としての４－アニリノ－キノリン化合物 Active JP7039579B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305862 2016-07-08
EP16305862.1 2016-07-08
PCT/EP2017/067306 WO2018007648A1 (en) 2016-07-08 2017-07-10 4-anilino-quinoline compounds as anti-cancer agents

Publications (3)

Publication Number Publication Date
JP2019521193A JP2019521193A (ja) 2019-07-25
JP2019521193A5 JP2019521193A5 (enExample) 2020-08-20
JP7039579B2 true JP7039579B2 (ja) 2022-03-22

Family

ID=56413606

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019521185A Active JP7039579B2 (ja) 2016-07-08 2017-07-10 抗癌剤としての４－アニリノ－キノリン化合物

Country Status (6)

Country Link
US (1) US20200181089A1 (enExample)
EP (1) EP3481806B1 (enExample)
JP (1) JP7039579B2 (enExample)
AU (1) AU2017294572B2 (enExample)
CA (1) CA3029889A1 (enExample)
WO (1) WO2018007648A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019134975A1 (en) 2018-01-05 2019-07-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Substituted halo-quinoline derivatives, method of preparation and applications thereof
CN113549018B (zh) * 2020-04-24 2024-02-27 中国药科大学 蛋白激酶抑制剂及其衍生物，制备方法、药物组合物和应用
EP4169904A1 (en) 2021-10-25 2023-04-26 Yukin Therapeutics Substituted quinolines as improved nf-kb-inducing kinase (nik) inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102249997A (zh) 2011-05-25 2011-11-23 沈阳化工大学 一组具有抗肿瘤活性的4-取代苯氨基喹啉化合物
CN103232444A (zh) 2013-04-18 2013-08-07 中国人民解放军军事医学科学院微生物流行病研究所 萘酚喹衍生物及其制备和其应用
WO2014130411A1 (en) 2013-02-22 2014-08-28 Emory University Tgf-beta enhancing compositions for cartilage repair and methods related thereto

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3075981A (en) * 1958-04-03 1963-01-29 Sterling Drug Inc 1-[aromatic-(lower-alkyl)]-4-(aromaticimino)-1, 4-dihydroquinolines and their preparation
BE640616A (enExample) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
WO2008089307A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102249997A (zh) 2011-05-25 2011-11-23 沈阳化工大学 一组具有抗肿瘤活性的4-取代苯氨基喹啉化合物
WO2014130411A1 (en) 2013-02-22 2014-08-28 Emory University Tgf-beta enhancing compositions for cartilage repair and methods related thereto
CN103232444A (zh) 2013-04-18 2013-08-07 中国人民解放军军事医学科学院微生物流行病研究所 萘酚喹衍生物及其制备和其应用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Dakshanamurthy, S et al，In-silico fragment-based identification of novelangiogenesis inhibitors，Bioorganic & Medicinal Chemistry Letters，Vol.17，2007年，p.4551-4556
Liu, D et al.，Synthesis and Anti-Tumor Activities of 4-Anilinoquinoline Derivatives，Molecules，Vol.21，2016年，p.1-8，URL:http://www.mdpi.com/1420-3049/21/1/21
OTEVREL,J. et al.，Antimycobacterial and photosynthetic electron transport inhibiting activity of ring-substituted 4-arylamino-7-chloroquinolinium chlorides，Molecules，2013年，Vol.18, No.9，p.10648-10670
REGISTRY[online]，2007.03.01, [Retrieved on 2021.04.05], Retrieved from：STN, CAS登録番号 924143-41-9
REGISTRY[online]，2010.08.04, [Retrieved on 2021.04.05], Retrieved from：STN, CAS登録番号 1235000-61-9
REGISTRY[online]，2010.08.05, [Retrieved on 2021.04.05], Retrieved from：STN, CAS登録番号 1235080-72-4

Also Published As

Publication number Publication date
CA3029889A1 (en) 2018-01-11
AU2017294572B2 (en) 2021-11-04
US20200181089A1 (en) 2020-06-11
AU2017294572A2 (en) 2019-05-09
AU2017294572A1 (en) 2019-01-24
EP3481806C0 (en) 2023-06-07
EP3481806A1 (en) 2019-05-15
EP3481806B1 (en) 2023-06-07
JP2019521193A (ja) 2019-07-25
WO2018007648A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
JP2024522293A (ja) ナトリウムチャネルのモジュレーターとしての置換テトラヒドロフラン類似体
JP2024520643A (ja) ナトリウムチャネルの調節因子としてのヒドロキシ及び（ハロ）アルコキシ置換テトラヒドロフラン
CN114945566A (zh) 作为钠通道调节剂的取代四氢呋喃
KR102271794B1 (ko) 항암 활성을 나타내는 벤젠 설폰아미드 티아졸 화합물
JP2019055974A (ja) ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ
TWI755788B (zh) 類鐸受體促效劑
CN111410661A (zh) 帽依赖性内切核酸酶抑制剂及其用途
JP7039579B2 (ja) 抗癌剤としての４－アニリノ－キノリン化合物
CN110156674A (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
JP6867998B2 (ja) ガンを処置するのに使用するための置換疎水性ベンゼンスルホンアミドチアゾール化合物
CN112055706B (zh) 取代的卤代-喹啉衍生物、其制备方法和应用
TWI829329B (zh) 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑
WO2018229139A1 (en) Novel compounds for use in cancer
JP7152078B2 (ja) ホウ酸塩ベースの薬物およびその使用
CA3149302A1 (en) Substituted cyclopropyl-2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
AU2017380492B2 (en) Sulfonyl amidine as indoleamine-2,3-dioxygenase inhibitor, and preparation method therefor and use thereof
CN110049768A (zh) 酚噻嗪衍生物及其使用方法
JP2016216446A (ja) ピロリジン−２，５−ジオン誘導体の多形形態、医薬組成物、およびｉｄｏ１阻害薬としての使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200710

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211018

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220309

R150 Certificate of patent or registration of utility model

Ref document number: 7039579

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250